Vaxcyte (PCVX) COO Wassil Jim Exercises Options and Sells Shares

What Happened

• Wassil Jim, Chief Operating Officer of Vaxcyte (PCVX), exercised stock options to acquire 2,250 shares at $5.35 per share (cost ~$12,038) and reported sales of 2,250 shares in two open‑market transactions that netted about $121,195. The sales were 861 shares at a weighted‑average $53.50 ($46,065) and 1,389 shares at a weighted‑average $54.09 ($75,130). The filing also shows a disposition of 2,250 derivative shares at $0, which is reported separately on the Form 4.

Key Details

• Transaction date: August 3, 2026; Form 4 filed August 5, 2026 (no late filing indicated in the provided data).
• Exercise: 2,250 shares acquired @ $5.35 = $12,038.
• Open‑market sales: 861 shares @ $53.50 = $46,065; 1,389 shares @ $54.09 = $75,130; total proceeds ≈ $121,195.
• Derivative disposition: 2,250 shares reported disposed @ $0 (reported separately as a derivative transaction).
• Shares owned after the transactions: not specified in the provided summary.
• Notable footnotes: sales were executed under a Rule 10b5‑1 trading plan adopted Dec 9, 2025 (F2). The sales prices are weighted averages with reported ranges (F3, F4). F1 notes inclusion of 781 shares acquired under the company ESPP on May 15, 2026. F5 indicates the option(s) exercised were fully vested and exercisable.

Context

• The filing shows an option exercise (transaction code M) and contemporaneous sales. A derivative disposal at $0 on Form 4 often reflects shares withheld or surrendered to cover option exercise costs or tax withholding (commonly seen with cashless exercises), while the separate open‑market sales were executed under a prearranged 10b5‑1 plan. These entries are routine insider transactions; the 10b5‑1 disclosure indicates the sales were preplanned rather than timed to recent company events.